[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.234.223.162. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    EXPAND ALL
    Concerning cross-reactivity of SARS-CoV-2 antibody testing in prevalence investigation
    Yang Xu, MD | Shanghai University of Medicine and Health Sciences
    Serological testing is a key investigative tool in the COVID-19 prevalence investigation and can identify an infected family or school cluster, especially patients with mild illness. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological testing may help diagnose suspected patients with negative polymerase chain reaction (PCR) results and those with mild or asymptomatic infections (1). This will allow a more accurate determination of the percentage of infected people.

    Jeremias et al. (2) reported SARS-CoV-2 IgG positive rates were 9.8% in healthcare workers and 16.7% in the local population, respectively. However, the authors used an Abbott Architect SARS-CoV-2 IgG CMIA
    test kit, which is designed to detect IgG antibodies to the nucleocapsid protein of SARS-CoV-2 (3).

    SARS-CoV-2 and SARS-CoV patients have cross-reactivity of spike receptor-binding domain (RBD) and nucleocapsid (N) protein. Lv et al. (4) reported plasma samples of patients with COVID-19 that showed significant cross-reactivity with SARS-CoV N protein. The author also reported plasma samples from patients with severe acute respiratory syndrome (SARS) that could significantly cross-react with SARS-CoV-2 spike RBD and N protein (4).

    Grifoni et al. (5) investigated donors who were not exposed to COVID-19 and found SARS-CoV-2 and seasonal “common cold” human coronaviruses patients have cross-reactivity of SARS-CoV-2 T cell epitopes. Approximately 50% SARS-CoV-2 N protein-specific CD4+ T cell responses in COVID-19 cases were detected among non-contact donors. It was determined that non-contact donors have cross-reactivity to SARS-CoV-2 N protein. If the patient shows the N protein cross-reaction and an anti-spike or nucleocapsid protein detection kit is used, it may affect the evaluation of the prevalence survey (1,5).

    Therefore, the cross-reactivity of SARS-CoV-2 antibody testing may affect prevalence survey. The authors should address the limitation of the test kit that is designed to detect IgG antibodies to the nucleocapsid protein of SARS-CoV-2 in the study.

    References

    1. Long Q, Liu B, Deng H, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 2020; 26: 845-848.
    2. Jeremias A, Nguyen J, Levine J, et al. Prevalence of SARS-CoV-2 infection among health care workers in a tertiary community hospital. JAMA Intern Med. Published online Aug 11, 2020. doi: 10.1001/jamainternmed.2020.4214.
    3. EUA authorized serology test performance. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance
    4. Lv H, Wu NC, Tsang OT, et al. Cross-reactive antibody response between SARSCoV-2 and SARS-CoV infections. Cell Rep. 2020; 31:107725. doi: 10.1016/j.celrep.2020.107725.
    5. Grifoni, A., Weiskopf, D., Ramirez, S.I., et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 2020; 181:1489–1501.
    CONFLICT OF INTEREST: None Reported
    READ MORE
    Views 13,476
    Citations 0
    Research Letter
    August 11, 2020

    Prevalence of SARS-CoV-2 Infection Among Health Care Workers in a Tertiary Community Hospital

    Author Affiliations
    • 1Department of Medicine, St Francis Hospital, The Heart Center, Roslyn, New York
    • 2Department of Biostatistics, St Francis Hospital, The Heart Center, Roslyn, New York
    • 3Department of Laboratory Medicine, St Francis Hospital, The Heart Center, Roslyn, New York
    JAMA Intern Med. Published online August 11, 2020. doi:10.1001/jamainternmed.2020.4214

    New York City and its surrounding metro area have emerged as an epicenter of the coronavirus disease 2019 (COVID-19) outbreak worldwide. A recent population survey1 for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies among those in New York state shows a prevalence of 21.2% in New York City and 16.7% in Long Island. Across the US, up to 11% of reported COVID-19 cases were found to be in health care professionals,2 but the true prevalence of COVID-19 among health care workers is unknown. The aim of the present study is to establish the rate of COVID-19 among health care workers by widespread screening for SARS-CoV-2 exposure.

    ×